Cannabinoids make marijuana the medicinal powerhouse we know it as. As unique compounds that activate receptors in your body, they can provide health benefits other medical compounds can’t. One of these cannabinoids is known as cannabichromevarin (CBCV).
CBCV has the molecular formula C19H26O2. We call it a propyl cannabinoid, which means it has a propyl chain in its molecular structure. Instead of having a pentyl chain like its counterpart, cannabichromene (CBC), it branches off to have a propyl chain. This means it can have similar effects to CBC, but with a few differences we should examine.
We have known about CBCV since 1975 when researchers at the University of Nagasaki isolated cannabichromevarin from a cannabis plant from Thailand. However, scientists haven’t conducted much research on the compound since its discovery.
It’s hard to say precisely what makes CBCV unique from other cannabinoids except for its molecular structure. Since we don’t have much research on the compound, we don’t know anything definitive about its effects on the human body. While some propyl cannabinoids work similarly to their counterparts, others have unique effects you can’t find in other cannabinoids.
Two notable examples of the ways a propyl chain can affect a cannabinoid’s properties are THCV and CBDV. CBDV and CBD have nearly identical effects, with CBDV specializing in specific health benefits. But, THCV can enhance or dampen the effects of THC, as well as act as an appetite suppressant instead of a stimulant. So, for all we know, CBCV could have unique potential — we just haven’t discovered it yet.
As we mentioned before, researchers don’t know much about CBCV and its impact on the human body. However, we can make some educated guesses about its medical potential.
CBCV could relieve seizures in children and infants. Researchers from the Regents of the University of California have a patent on an anticonvulsant drug for infants dealing with seizures. While the medicine will mainly contain cannabidiol (CBD), the patent mentions CBC and CBCV as potential components. The patent doesn’t prove CBCV can relieve seizures, but it proves researchers have enough data to express interest in its possible anticonvulsant properties.
If CBCV turns out to have similar medical benefits to CBC, it could help patients without making them feel impaired. CBC doesn’t have any psychoactive properties, so it can’t cause a “high” or other mental effects. But, it can still relieve pain, reduce inflammation and improve depression symptoms. In the case that CBCV provides similar help to CBC, it could make these results even stronger.
Assuming CBCV has similar medical properties to CBC, it could help patients with health issues like:
If it has anticonvulsant properties, it can also relieve epileptic seizures.
To keep track of the latest developments in medical marijuana research, read our blog updates. We always make sure update our readers as soon as possible if scientists find any breakthroughs.
This information is not provided by medical professionals and is intended only to complement, and not to replace or contradict, any health or medical advice or information provided by healthcare professionals. If you have any questions, please contact your doctor or other healthcare professional.